Latest market price
19.12
+0.63+3.41%
News
Up 3.4% — Healthcare Realty Trust Q3 Earnings Call Highlights (marketbeat.com).
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -0.14 | Insider Own | 1.66% | Shs Outstand | 347.00M | Perf Week | 6.34% |
| Market Cap | 6.63B | Forward P/E | — | EPS next Y | 0.07 | Insider Trans | -0.81% | Shs Float | 340.39M | Perf Month | 9.44% |
| Enterprise Value | 11.10B | PEG | — | EPS next Q | 0.01 | Short Float | 5.14% | Perf Quarter | -5.67% | ||
| Income | -46.00M | P/S | 5.85 | EPS this Y | — | Short Ratio | 4.42 | Perf Half Y | -2.35% | ||
| Sales | 1.13B | P/B | 1.60 | EPS next Y | — | ROA | -0.50% | Short Interest | 17.49M | Perf YTD | 12.80% |
| Book/sh | 11.92 | P/C | — | EPS next 5Y | — | ROE | -1.04% | 52W High | 22.04 -13.25% | Perf Year | 7.66% |
| Cash/sh | 0.05 | P/FCF | 60.31 | EPS past 3/5Y | — | ROIC | 2.96% | 52W Low | 16.31 17.23% | Perf 3Y | 32.41% |
| Dividend Est. | 0.96 (5.02%) | EV/EBITDA | 15.55 | Sales past 3/5Y | 8.17% 9.95% | Gross Margin | 41.04% | Volatility | 2.92% 2.31% | Perf 5Y | -41.76% |
| Dividend TTM | 0.96 (5.02%) | EV/Sales | 9.79 | EPS Y/Y TTM | — | Oper. Margin | 22.92% | ATR (14) | 0.45 | Perf 10Y | -41.42% |
| Dividend Ex-Date | Nov 10, 2026 | Quick Ratio | 0.31 | Sales Y/Y TTM | -5.89% | Profit Margin | -3.96% | RSI (14) | 66.66 | Recom | 2.80 |
| Dividend Gr. 3/5Y | -45.68% -12.54% | Current Ratio | 0.31 | EPS Q/Q | 70.59% | SMA20 | 8.69% | Beta | 0.77 | Target Price | 22.00 |
| Payout | — | Debt/Eq | 1.09 | Sales Q/Q | -3.69% | SMA50 | 5.24% | Rel Volume | 2.29 | Prev Close | 18.49 |
| Employees | 539 | LT Debt/Eq | 1.00 | Earnings | Feb 11 | SMA200 | 1.47% | Avg Volume | 4.49M | Price | 19.12 |
| IPO Date | May 27, 1993 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -737.35% 4.13% | Net Debt/EBITDA | 6.26 | Volume | 10,270,587 | Change | 3.41% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-20-26 | Upgrade | Deutsche Bank | Hold → Buy | $23 |
| Sep-15-26 | Reiterated | Jefferies | Buy | $20 |
| Sep-01-26 | Reiterated | Wells Fargo | Equal Weight | $19 → $20 |
| Aug-07-26 | Reiterated | RBC Capital | Sector Perform | $21 → $22 |
| Jul-31-26 | Reiterated | Cantor Fitzgerald | Overweight | $22 → $24 |
| Jul-08-26 | Reiterated | UBS | Neutral | $20 → $21 |
| Jun-16-26 | Resumed | Raymond James | Outperform | $24 |
| Jun-12-26 | Reiterated | BTIG | Buy | $20 → $22 |
| May-14-26 | Reiterated | RBC Capital | Sector Perform | $19 → $21 |
| May-13-26 | Reiterated | UBS | Neutral | $18 → $20 |
Latest News· Times ET
Oct-30-26
02:38PM
Oct-29-26
Oct-29-2608:01PM
06:16PM
04:01PM
Oct-25-26
Oct-25-2612:00PM
Oct-23-26
Oct-23-2611:00AM
Oct-20-26
Oct-18-26
Oct-18-2607:00PM
Oct-13-26
Oct-13-2601:16PM
Oct-12-26
Oct-12-2604:05PM
Oct-07-26
Oct-05-26
Oct-05-2605:15PM
Company
Healthcare Realty Trust operates as a Real Estate Investment Trust (REIT), specializing in the acquisition, development, financing, and active management of income-generating real estate assets, predominantly serving outpatient healthcare providers throughout the United States. By September 30, 2020, its extensive portfolio comprised 211 properties located across 24 states, collectively spanning 15.5 million square feet and valued at approximately $5.5 billion. The company further provided comprehensive leasing and property management solutions for 11.9 million square feet nationwide.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,134 | 1,181 | 1,268 | 1,344 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 668 | 1,577 | 1,824 | 1,962 | — | — | — | — | — | |
| Gross Profit | 465 | -396 | -555 | -618 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 43 | 0 | 0 | 0 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 161 | -491 | -592 | -668 | — | — | — | — | — | |
| Operating Income | 260 | 95 | 36 | 50 | — | — | — | — | — | |
| Interest Expense | 172 | 205 | 255 | 269 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -133 | -139 | -445 | -63 | — | — | — | — | — | |
| Net Income Before Taxes | -45 | -249 | -664 | -282 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -46 | -246 | -654 | -278 | — | — | — | — | — | |
| Net Income From Continuing Operations | -45 | -249 | -664 | -282 | — | — | — | — | — | |
| Net Income | -46 | -246 | -654 | -278 | — | — | — | — | — | |
| EPS (Recurring) | -0.14 | -0.71 | -1.81 | -0.74 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.14 | -0.71 | -1.81 | -0.74 | — | — | — | — | — | |
| EPS (Diluted) | -0.14 | -0.71 | -1.81 | -0.74 | — | — | — | — | — | |
| EBITDA | 714 | 520 | 314 | 762 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.75 | 5.02 | 4.89 | 4.86 | — | — | — | — | — | |
| Gross Margin | 41.01 | -33.53 | -43.77 | -45.98 | — | — | — | — | — | |
| Operating Margin | 22.93 | 8.04 | 2.84 | 3.72 | — | — | — | — | — | |
| Net Margin | -4.06 | -20.83 | -51.58 | -20.68 | — | — | — | — | — | |
| Shares Outstanding | 341 | 350 | 366 | 379 | — | — | — | — | — | |
| Market Capitalization | 6,520 | 5,933 | 6,204 | 6,530 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hull Robert E | EVP and COO | Sep 08 '26 | Sale | 19.11 | 21,000 | 401,310 | 276,338 | Sep 09 |
| Callaway Amanda L | SVP & Chief Accounting Officer | Jun 23 '26 | Sale | 20.37 | 25,767 | 524,874 | 109,954 | Jun 23 |
| Bohjalian Thomas N | Director | Mar 06 '26 | Buy | 18.09 | 10,000 | 180,900 | 85,520 | Mar 06 |
| Gabbay Daniel | EVP, Chief Financial Officer | Mar 04 '26 | Buy | 18.74 | 10 | 187 | 10 | Mar 05 |
| Wilson Julie F. | EVP, Chief Admin. Officer | Sep 05 '25 | Sale | 18.00 | 15,000 | 270,000 | 113,419 | Sep 05 |
| Bohjalian Thomas N | Director | Aug 13 '25 | Buy | 16.46 | 10,000 | 164,600 | 75,520 | Aug 13 |
| Bohjalian Thomas N | Director | May 13 '25 | Buy | 14.71 | 2,500 | 36,775 | 56,502 | May 14 |
| Leupp Jay P | Director | Dec 20 '24 | Buy | 16.85 | 1,000 | 16,850 | 33,830 | Dec 20 |
| WOOD DONALD C | Director | Dec 19 '24 | Buy | 16.86 | 5,900 | 99,474 | 5,900 | Dec 20 |
| Hull Robert E | EVP and COO | Dec 17 '24 | Sale | 17.48 | 10,000 | 174,820 | 171,400 | Dec 17 |
| Lyle Peter F SR | Director | Dec 13 '24 | Buy | 17.21 | 10,000 | 172,100 | 26,576 | Dec 16 |
| Bohjalian Thomas N | Director | Nov 22 '24 | Buy | 17.33 | 11,750 | 203,595 | 54,002 | Nov 22 |
| SINGLETON JOHN KNOX | Director | Sep 05 '24 | Buy | 18.24 | 6,500 | 118,564 | 57,082 | Sep 06 |
| Kilroy James Joseph IV | Director | Sep 05 '24 | Buy | 18.26 | 12,900 | 235,554 | 25,300 | Sep 06 |
| Bohjalian Thomas N | Director | Sep 04 '24 | Buy | 17.88 | 14,000 | 250,320 | 42,252 | Sep 04 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.